|Articles|February 8, 2004
Enbrel manufacturer speaks of post-approval plan
Washington, D.C. Officials of Amgen spoke of teaching patientsabout biologic treatments of psoriasis, dermatologists spreading the wordabout the new class of drugs, and the physician-patient relationship asits Enbrel (etanercept) added to the resume leading it toward approval bythe U.S. Food and Drug Administration.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5













